These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38906503)

  • 1. Economic analysis of foregoing Rh immunoglobulin for bleeding in pregnancy <12 weeks gestation.
    Horvath S; Wang L; Calo W; Yazer MH
    Contraception; 2024 Nov; 139():110530. PubMed ID: 38906503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs and benefits of non-invasive fetal RhD determination.
    Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(15):1-160. PubMed ID: 33240456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rh(O)D immune globulin products for prevention of alloimmunization during pregnancy.
    Aitken SL; Tichy EM
    Am J Health Syst Pharm; 2015 Feb; 72(4):267-76. PubMed ID: 25631833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Society for Maternal-Fetal Medicine Statement: RhD immune globulin after spontaneous or induced abortion at less than 12 weeks of gestation.
    ; Prabhu M; Louis JM; Kuller JA;
    Am J Obstet Gynecol; 2024 May; 230(5):B2-B5. PubMed ID: 38417536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should cell-free DNA testing be used to target antenatal rhesus immune globulin administration?
    Ma KK; Rodriguez MI; Cheng YW; Norton ME; Caughey AB
    J Matern Fetal Neonatal Med; 2016; 29(11):1866-70. PubMed ID: 26169705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-benefit analysis of indirect antiglobulin screening in Rh(D)-negative women at 28 weeks of gestation.
    Abbey R; Dunsmoor-Su R
    Obstet Gynecol; 2014 May; 123(5):938-945. PubMed ID: 24785843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis.
    Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S
    BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell free fetal DNA to triage antenatal rhesus immune globulin: Is it really cost-effective in the United States?
    Moise KJ; Hashmi SS; Markham K; Argoti PS; Bebbington M
    Prenat Diagn; 2019 Feb; 39(3):238-247. PubMed ID: 30610742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for RhD immunisation in a high coverage prevention programme of antenatal and postnatal RhIg: a nationwide cohort study.
    Slootweg YM; Zwiers C; Koelewijn JM; van der Schoot E; Oepkes D; van Kamp IL; de Haas M
    BJOG; 2022 Sep; 129(10):1721-1730. PubMed ID: 35133072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rh immune globulin immunoprophylaxis after RhD-positive red cell exposure in RhD-negative patients via transfusion: A survey of practices.
    Lu W; Stephens L; Shmookler A; O'Brien K; Karp JK; Hermelin D; Bakhtary S; Almozain N; George M; Fung M
    Transfusion; 2024 May; 64(5):839-845. PubMed ID: 38534065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the cost of Rh testing and prophylaxis in early pregnancy: A time-driven activity-based costing study.
    Gilmore EV; Russell LB; Harvie HS; Schreiber CA
    Contraception; 2024 Aug; 136():110468. PubMed ID: 38648923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of noninvasive fetal RhD blood group genotyping in nonalloimmunized and alloimmunized pregnancies.
    Gajic-Veljanoski O; Li C; Schaink AK; Guo J; Shehata N; Charames GS; de Vrijer B; Clarke G; Pechlivanoglou P; Okun N; Kandel R; Dooley J; Higgins C; Ng V; Sikich N
    Transfusion; 2022 May; 62(5):1089-1102. PubMed ID: 35170037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do Rh-negative women with first trimester spontaneous abortions need Rh immune globulin?
    Hannafin B; Lovecchio F; Blackburn P
    Am J Emerg Med; 2006 Jul; 24(4):487-9. PubMed ID: 16787810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.
    Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C
    BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation.
    Saramago P; Yang H; Llewellyn A; Walker R; Harden M; Palmer S; Griffin S; Simmonds M
    Health Technol Assess; 2018 Mar; 22(13):1-172. PubMed ID: 29580376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive Fetal RhD Blood Group Genotyping: A Systematic Review of Economic Evaluations.
    Gajic-Veljanoski O; Li C; Schaink AK; Guo J; Higgins C; Shehata N; Okun N; de Vrijer B; Pechlivanoglou P; Ng V; Sikich N
    J Obstet Gynaecol Can; 2021 Dec; 43(12):1416-1425.e5. PubMed ID: 34390866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation.
    Pilgrim H; Lloyd-Jones M; Rees A
    Health Technol Assess; 2009 Feb; 13(10):iii, ix-xi, 1-103. PubMed ID: 19210896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis.
    Neovius M; Tiblad E; Westgren M; Kublickas M; Neovius K; Wikman A
    BJOG; 2016 Jul; 123(8):1337-46. PubMed ID: 26663771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Spontaneous antepartal RhD alloimmunization].
    Studničková M; Holusková I; Durdová V; Kratochvílová T; Strašilová P; Marková I; Lubušký M
    Ceska Gynekol; 2015 Dec; 80(6):401-4. PubMed ID: 26741153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.